Literature DB >> 30968756

Hepatic Insulin Clearance: Mechanism and Physiology.

Sonia M Najjar1,2, Germán Perdomo3.   

Abstract

Upon its secretion from pancreatic β-cells, insulin reaches the liver through the portal circulation to exert its action and eventually undergo clearance in the hepatocytes. In addition to insulin secretion, hepatic insulin clearance regulates the homeostatic level of insulin that is required to reach peripheral insulin target tissues to elicit proper insulin action. Receptor-mediated insulin uptake followed by its degradation constitutes the basic mechanism of insulin clearance. Upon its phosphorylation by the insulin receptor tyrosine kinase, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) takes part in the insulin-insulin receptor complex to increase the rate of its endocytosis and targeting to the degradation pathways. This review summarizes how this process is regulated and how it is associated with insulin-degrading enzyme in the liver. It also discusses the physiological implications of impaired hepatic insulin clearance: Whereas reduced insulin clearance cooperates with increased insulin secretion to compensate for insulin resistance, it can also cause hepatic insulin resistance. Because chronic hyperinsulinemia stimulates hepatic de novo lipogenesis, impaired insulin clearance also causes hepatic steatosis. Thus impaired insulin clearance can underlie the link between hepatic insulin resistance and hepatic steatosis. Delineating these regulatory pathways should lead to building more effective therapeutic strategies against metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30968756      PMCID: PMC6734066          DOI: 10.1152/physiol.00048.2018

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN: 1548-9221


  221 in total

Review 1.  Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action.

Authors:  T F Osborne
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

Review 2.  Signaling pathways in insulin action: molecular targets of insulin resistance.

Authors:  J E Pessin; A R Saltiel
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  The differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor.

Authors:  P Soni; M Lakkis; M N Poy; M A Fernström; S M Najjar
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

4.  Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.

Authors:  S J Koopmans; R S Kushwaha; R A DeFronzo
Journal:  Metabolism       Date:  1999-03       Impact factor: 8.694

5.  Comparison of the intracellular trafficking of two alternatively spliced isoforms of pp120, a substrate of the insulin receptor tyrosine kinase.

Authors:  C V Choice; M N Poy; P Formisano; S M Najjar
Journal:  J Cell Biochem       Date:  1999-11       Impact factor: 4.429

6.  Cell adhesion properties and effects on receptor-mediated insulin endocytosis are independent properties of pp120, a substrate of the insulin receptor tyrosine kinase.

Authors:  P Soni; K A Al-Hosaini; M A Fernström; S M Najjar
Journal:  Mol Cell Biol Res Commun       Date:  1999-05

7.  Comparison of expression patterns and cell adhesion properties of the mouse biliary glycoproteins Bbgp1 and Bbgp2.

Authors:  J Robitaille; L Izzi; E Daniels; B Zelus; K V Holmes; N Beauchemin
Journal:  Eur J Biochem       Date:  1999-09

8.  Degradation of amylin by insulin-degrading enzyme.

Authors:  R G Bennett; W C Duckworth; F G Hamel
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

9.  Free fatty acids impair hepatic insulin extraction in vivo.

Authors:  S R Wiesenthal; H Sandhu; R H McCall; V Tchipashvili; H Yoshii; K Polonsky; Z Q Shi; G F Lewis; A Mari; A Giacca
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

10.  Roles of insulin resistance and obesity in regulation of plasma insulin concentrations.

Authors:  C N Jones; F Abbasi; M Carantoni; K S Polonsky; G M Reaven
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-03       Impact factor: 4.310

View more
  62 in total

1.  Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross-sectional and longitudinal study from the Yale Pediatric NAFLD cohort.

Authors:  Domenico Tricò; Alfonso Galderisi; Andrea Mari; David Polidori; Brittany Galuppo; Bridget Pierpont; Stephanie Samuels; Nicola Santoro; Sonia Caprio
Journal:  Diabetes Obes Metab       Date:  2020-05-31       Impact factor: 6.577

2.  Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.

Authors:  Gabriella V Hernandez; Victoria A Smith; Megan Melnyk; Matthew A Burd; Kimberly A Sprayberry; Mark S Edwards; Daniel G Peterson; Darin C Bennet; Rob K Fanter; Daniel A Columbus; Juan P Steibel; Hunter Glanz; Chad Immoos; Margaret S Rice; Tasha M Santiago-Rodriguez; Jason Blank; Jennifer J VanderKelen; Christopher L Kitts; Brian D Piccolo; Michael R La Frano; Douglas G Burrin; Magdalena Maj; Rodrigo Manjarin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-31       Impact factor: 4.052

3.  Pancreatic β-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and β-cell functional immaturity.

Authors:  Cristina M Fernández-Díaz; Beatriz Merino; José F López-Acosta; Pilar Cidad; Miguel A de la Fuente; Carmen D Lobatón; Alfredo Moreno; Malcolm A Leissring; Germán Perdomo; Irene Cózar-Castellano
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-03       Impact factor: 4.310

Review 4.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

5.  Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial.

Authors:  Fatemeh Rahimi Sakak; Nazanin Moslehi; Mahtab Niroomand; Parvin Mirmiran
Journal:  Eur J Nutr       Date:  2020-11-07       Impact factor: 5.614

6.  Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.

Authors:  Jehnan Liu; Harrison T Muturi; Saja S Khuder; Raghd Abu Helal; Hilda E Ghadieh; Sadeesh K Ramakrishnan; Meenakshi K Kaw; Sumona Ghosh Lester; Ahmed Al-Khudhair; Philip B Conran; Khew-Voon Chin; Cara Gatto-Weis; Sonia M Najjar
Journal:  Metabolism       Date:  2020-03-21       Impact factor: 8.694

7.  Pre-diabetes and COVID-19, could we be missing the silent killer?

Authors:  Aubrey Mbulelo Sosibo; Andile Khathi
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-20

8.  Peripheral and central regulation of insulin by the intestine and microbiome.

Authors:  Jonathan D Schertzer; Tony K T Lam
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-14       Impact factor: 4.310

9.  Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics.

Authors:  Gordon I Smith; David C Polidori; Mihoko Yoshino; Monica L Kearney; Bruce W Patterson; Bettina Mittendorfer; Samuel Klein
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

10.  Tubular Secretory Clearance Is Associated With Whole-Body Insulin Clearance.

Authors:  Matthew P Huber; Leila R Zelnick; Kristina M Utzschneider; Steven E Kahn; Ian H de Boer; Bryan R Kestenbaum
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.